AbbVie Inc. $ABBV Shares Sold by Sumitomo Mitsui DS Asset Management Company Ltd

Posted by George Bondi on Oct 21st, 2026

Sumitomo Mitsui DS Asset Management Company Ltd trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 10.1% during the third quarter, HoldingsChannel.com reports. The firm owned 291,632 shares of the company’s stock after selling 32,919 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in AbbVie were worth $76,288,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ABBV. CWA Asset Management Group LLC increased its holdings in AbbVie by 0.4% during the 3rd quarter. CWA Asset Management Group LLC now owns 86,568 shares of the company’s stock worth $22,645,000 after acquiring an additional 309 shares during the period. CFS Investment Advisory Services LLC boosted its holdings in AbbVie by 0.3% in the 3rd quarter. CFS Investment Advisory Services LLC now owns 24,252 shares of the company’s stock valued at $6,468,000 after purchasing an additional 77 shares during the period. Grandview Asset Management LLC boosted its holdings in AbbVie by 1.5% in the 3rd quarter. Grandview Asset Management LLC now owns 18,260 shares of the company’s stock valued at $4,777,000 after purchasing an additional 273 shares during the period. Investment Research Partners LLC boosted its holdings in AbbVie by 4.6% in the 3rd quarter. Investment Research Partners LLC now owns 5,314 shares of the company’s stock valued at $1,390,000 after purchasing an additional 233 shares during the period. Finally, Smithbridge Asset Management Inc. DE grew its position in shares of AbbVie by 5.3% during the 3rd quarter. Smithbridge Asset Management Inc. DE now owns 30,750 shares of the company’s stock valued at $8,044,000 after purchasing an additional 1,535 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Promising Crohn’s disease results strengthen AbbVie’s pipeline. In a Phase 2a study, investigational ABBV-466, a dual-targeting therapy against IL-23 and integrin α4β7, produced higher endoscopic remission rates than either monotherapy at Week 12, with the treatment advantage widening by Week 24. The results suggest a potential future combination option in inflammatory bowel disease and helped reinforce AbbVie’s immunology strategy. AbbVie Presents Data for ABBV-466
Positive Sentiment: Analysts see continued growth in neuroscience. AbbVie’s neuroscience franchise is projected to deliver nearly 16% revenue growth in the third quarter, supported by established products and newer Parkinson’s disease therapies. This offers another source of expansion as the company manages the loss of exclusivity for Humira. AbbVie’s Neuroscience Franchise
Positive Sentiment: Strong cash generation supports the investment case. A comparison with Vertex highlighted AbbVie’s substantial free cash flow and its ability to navigate Humira’s patent expiration, factors that may support dividends, business development and pipeline investment. AbbVie vs. Vertex Pharmaceuticals
Neutral Sentiment: McLaren Formula 1 partnership raises AbbVie’s visibility. The multiyear sponsorship and “Race to Innovate” campaign will promote awareness of immune-mediated diseases and provide charitable donations tied to McLaren’s championship points. The initiative is strategically positive for brand recognition but is unlikely to materially affect near-term earnings. AbbVie Named Official Pharmaceutical Partner of McLaren
Negative Sentiment: Competitive risk remains in immunology. Reports that Rapport Therapeutics may enter a market estimated at $4.3 billion—and positive commentary surrounding Spyre Therapeutics’ ulcerative-colitis combination approach—highlight potential future competition. However, these programs remain developmental and do not appear to change AbbVie’s near-term results. Rapport Enters AbbVie Market

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ABBV shares. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and upped their price target for the stock from $235.00 to $300.00 in a report on Thursday, August 13th. HSBC increased their price objective on AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Rothschild & Co Redburn lifted their price objective on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Finally, Guggenheim restated a “buy” rating and set a $288.00 target price on shares of AbbVie in a research report on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $277.18.

Get Our Latest Stock Report on ABBV

AbbVie Trading Up 2.1%

ABBV stock opened at $288.66 on Wednesday. The company’s 50 day moving average is $264.22 and its 200 day moving average is $240.39. The stock has a market cap of $510.01 billion, a price-to-earnings ratio of 81.54, a price-to-earnings-growth ratio of 1.29 and a beta of 0.24. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40.

AbbVie (NYSE:ABBV – Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same period in the previous year, the business posted $2.97 earnings per share. AbbVie’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 13.94 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie’s dividend payout ratio is presently 195.48%.

AbbVie Company Profile

(Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.